![]() |
市场调查报告书
商品编码
1433455
全球迴旋加速器市场 2023-2030Global Cyclotron Market 2023-2030 |
在预测期内(2023-2030年),全球迴旋加速器市场预计将以11.2%的CAGR增长。市场增长归因于癌症患病率不断上升和诊断成像程序的使用不断增加等因素。根据世界卫生组织的数据,癌症是全球主要死亡原因,2020 年将导致近 1,000 万人死亡,即近六分之一的死亡。 2020年新增癌症病例包括乳癌(226万例)、肺癌(221万例)、结肠癌和直肠癌(193万例)。多种生活方式因素会导致癌症的发生,例如加工肉类摄取量高、水果和蔬菜摄取量低、久坐的生活方式、肥胖、吸烟和过量饮酒。
全球迴旋加速器市场按产品和应用进行细分。根据产品,市场细分为迴旋加速器10-12MeV、迴旋加速器16-18MeV、迴旋加速器19-24MeV和24MeV以上迴旋加速器。此外,根据应用,市场细分为医疗和工业。在这些产品中,迴旋加速器10-12 MeV 细分市场预计将占据相当大的市场份额,因为迴旋加速器10-12 MeV 系列有助于生产用于医学成像的放射性同位素,特别是在正子断层扫描中(宠物)。
在这些应用中,医疗细分市场预计将在全球迴旋加速器市场中占据相当大的份额。此细分市场的成长归因于各种医学影像技术(例如正子断层扫描(PET))在放射性药物生产中的使用不断增加,以及对准确疾病诊断的核子医学程序的需求不断增加。核子医学程序对于检测和监测各种医疗状况至关重要。根据世界核能协会统计,全球每年约有4,000万例核医手术,年增率为5.0%。全球有超过 10,000 家医院在医学中使用放射性同位素,约 90% 的手术用于诊断。诊断中最常使用的放射性同位素是锝-99 (Tc-99m),约占全球所有核子医学程序的 80% 和核子医学诊断扫描的 85%。
全球迴旋加速器市场根据地理位置进一步细分,包括北美(美国和加拿大)、欧洲(英国、义大利、西班牙、德国、法国和欧洲其他地区)、亚太地区(印度、中国、日本、韩国、亚洲其他地区)以及世界其他地区(中东和非洲以及拉丁美洲。其中,预计亚太地区在预测期内的CAGR最高。医疗技术不断进步,可支配收入不断增加以及新兴经济体医疗基础设施的改善正在推动亚太地区的迴旋加速器市场。
癌症发病率的上升、政府的有利倡议以及高度发展的医疗基础设施是推动该地区市场的关键因素。根据美国癌症协会的《2022 年癌症事实与数据》,预计 2022 年美国将新增约 1,918,030 例癌症病例,并有 609,360 人因癌症死亡。该地区如此高的癌症发病率预计将增加癌症的采用率迴旋加速器用于癌症诊断,推动了该地区的市场成长。
服务于迴旋加速器市场的主要公司包括Siemens Medical Solutions USA, Inc.、IBA Radiopharma Solutions、GE HealthCare、Advanced Cyclotron Systems, Inc.等。市场参与者透过各种策略(包括併购、合作、合作、融资和新产品发布),为市场成长做出了巨大贡献,以保持市场竞争力。例如,2023年1月,Fusion Pharmaceuticals Inc.和BWX Technologies, Inc.的子公司BWXT Medical Ltd.签订了供应actinium-225的优先合作伙伴协议。根据协议,BWXT Medical 按批量定价提供 Fusion 预定数量的锕供应需求。
Global Cyclotron Market Size, Share & Trends Analysis Report by Product (Cyclotron 10-12MeV, Cyclotron 16-18MeV, Cyclotron 19-24MeV, and Cyclotron above 24MeV), by Application(Medical, and Industrial), Forecast Period (2024-2031)
The global cyclotron market is anticipated to grow at a CAGR of 11.2% during the forecast period (2023-2030).The market growth is attributed to factors such as the growing prevalence of cancer and the increasing use of diagnostic imaging procedures. According to the World Health Organization, cancer is a leading cause of death around the globe, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. In terms of new cases of cancer in 2020 included breast (2.26 million cases);lung (2.21 million cases);colon and rectum (1.93 million cases). Several lifestyle factors contribute to the development of cancer such as a high intake of processed meats and low intake of fruits and vegetables, a sedentary lifestyle, obesity, smoking, and excessive alcohol consumption.
The global cyclotron market is segmented on the product and application. Based on the product, the market is sub-segmented into cyclotron 10-12MeV, cyclotrons 16-18MeV, cyclotron 19-24MeV, and cyclotron above 24MeV.Further, based on application, the market is sub-segmented into medical, and industrial. Among the products, the cyclotron 10-12 MeV sub-segment is anticipated to hold a considerable share of the market, owing to the cyclotron 10-12 MeV range being instrumental in the production of radioisotopes used for medical imaging, particularly in positron emission tomography (PET).
Among the applications, the medical sub-segment is expected to hold a considerable share of the global cyclotron market. The segmental growth is attributed to the increasing use in radiopharmaceutical production in various medical imaging techniques, such as positron emission tomography (PET), and increasing demand in nuclear medicine procedures for accurate disease diagnosis. Nuclear medicine procedures are vital for detecting and monitoring various medical conditions. According to the World Nuclear Association, about 40 million procedures are carried out each year globally with nuclear medicines, with an annual growth rate of 5.0% per annum. Over 10,000 hospitals globally use radioisotopes in medicine, and about 90% of the procedures are for diagnosis. The most common radioisotope used in diagnosis is technetium-99 (Tc-99m), accounting for about 80% of all nuclear medicine procedures and 85% of diagnostic scans in nuclear medicine around the globe.
The global cyclotron market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, Asia Pacific is anticipated to exhibit highest CAGR during the forecast period. The advancing medical technologies, rising disposable income, and improving healthcare infrastructure in emerging economies are driving the cyclotron market in the Asia-Pacific.
The rising prevalence of cancer, favorable government initiatives, and highly developed healthcare infrastructure is a key factor driving the regional market. According to the American Cancer Society 'Cancer Facts & Figures 2022', around 1,918,030 new cancer cases and 609,360 mortalities due to cancers are estimated in the US in the year 2022. Such a high incidence of cancers in this region is anticipated to increase the adoption of cyclotrons for the diagnosis of cancer, driving market growth in this region.
The major companies serving the cyclotron market include Siemens Medical Solutions USA, Inc., IBA Radiopharma Solutions, GE HealthCare, Advanced Cyclotron Systems, Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2023, Fusion Pharmaceuticals Inc., and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. entered into a preferred partner agreement for the supply of actinium-225. Under the agreement, BWXT Medical offered predetermined amounts of Fusion's actinium supply needs at volume-based pricing.